Hyderabad & US, July 30th 2007
GVK Biosciences (GVK BIO) today announced that it has signed a material transfer agreement with the Genomics group of the US Food and Drug Administration (USFDA) to share information from its Clinical Biomarker Database. The Genomics group at the FDA will use the database in its VGDS (Voluntary Genomics Data Submission program) as well as in its internal research. GVK BIO will use the feedback from the FDA to further optimize the content and capabilities of the database to meet Reviewers’ needs. Currently, the GVK BIO database contains over 278 different fields for clinically reported biomarkers captured from the published literature. Data ranging from clinical to the preclinical stage has been captured. The database may be useful for design, validation and as a knowledgebase of studies where biomarkers were reported.
G V Sanjay Reddy, Chief Executive Officer, GVK BIO: “We are happy to be working with the USFDA on the biomarker database. It is the first of a kind collaboration in the Informatics field for a company based out of India”.
Sreeni Devidas, Vice President Business Development commented: “The agreement with the FDA further validates the positioning of GVK BIO as a leader in the life-sciences database industry. The product will be very useful to researchers, in the emerging area of Biomarker research, in the Pharmaceutical and Biotech Industry as well as academia”.
About Informatics at GVK BIO
The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to biotech and Pharma companies.
About GVK BIO
GVK Biosciences is one of India’s premier Contract Research Organizations, providing an integrated platform of research services across the Pharma R&D value chain to a growing number of global Pharma and Biotech companies. The company combines science, innovation and resources to help clients address their Drug Discovery and Development challenges. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Gurgaon.
For any further information, please contact: